Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002)

A Phase 1, Double-Blind, Placebo-Controlled, Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-7240 in Healthy Chinese Participants.

The goal of this study is to learn about the safety of tulisokibart in healthy participants and what happens to tulisokibart over time when participants receive treatment intravenously versus subcutaneously.

Inclusion Criteria:

Inclusion Criteria include, but are not limited to:

• Be in good health
• Has a body mass index (BMI) ≥18 and ≤28 kg/m^2 and weight ≥40.0 kg
• Continuous non-smoker who has not used tobacco or nicotine-containing products for at least 3 months prior to the dosing of study drug

Exclusion Criteria:

Exclusion Criteria include, but are not limited to:

• History of cancer (malignancy)
• Has positive serum test for human immunodeficiency virus (HIV), hepatitis C or hepatitis B virus infection